Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

04:05 EDT 2nd July 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 25,000+

Wednesday 1st July 2015

Overcoming Challenges in Sequence Analysis of FFPE Tissue Due to Heterogeneity: Silicon Biosystems DEPArray™ Technology Offers a Revolutionary Approach to Understanding Complex Cancer Genomics in FFPE Samples

Silicon Biosystems, a Bologna (Italy) and San Diego (CA, USA) based biotech company that is part of the pharmaceutical Menarini Group, presented recent findings obtained with its breakthrough state-of-the-art DEPArray™ technology in the characterization of pure tumor cell subpopulations derived from formalin fixed paraffin embedded (FFPE) tissue samples ...

Jaguar Completes Study in Dogs with Chemotherapy-Induced Diarrhea with Commercial Formulation of Canalevia

Jaguar Targeting First Prescription Product Launch in Early 2016 Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it recently completed a multi-site pilot saf...

Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain

TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints in Phase 2b study in pain due to osteoarthritis of the knee. TV-45070 demonstrated a favorable safety and tolerability profile, with no drug-related serious adverse events. Low drug plasma levels couple...

Transgenomic Launches Ultra-High Sensitive ICEme™ Mutation Enrichment Kits Enabling Turbocharged Cancer Research on Existing Platforms

Multiplexed ICE COLD-PCR™ Technology Enables Use of Tissue or Liquid Biopsy Samples and Provides Up to 500-Fold Increase in Mutation Detection with LOD to 0.01% Customizable Kits Work on All Platforms – Initial Menu Offers 17 Clinically Actionable Exons/Mutations for Use as Single Mutations or in Combination Transgenomic, Inc. (NASD...

Enzyme provides built-in protection against atherosclerosis

ANN ARBOR, Mich., July 1, 2015 /PRNewswire-USNewswire/ -- Staying active, never smoking and controlling diabetes and cholesterol can prevent hardening of the arteries, but effective treatment of atherosclerosis could come down to harnessing an enzyme already built in to the blood vessels. Atherosclerosis is the usual cause of heart attacks, strokes and peripheral vascular disease – conditio...

Tenax Therapeutics Spotlights Academic Publication on Levosimendan in Cardiac Surgery

Meta-analysis reports that use of levosimendan reduces mortality in adult cardiac surgery patients with left ventricular dysfunction Enrollment ongoing for Company’s Phase 3 LEVO-CTS trial for levosimendan in LCOS Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and...

Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare Conference

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Cantor Fitzgerald Inaugural “From Bench to Bedside” Healthcare Conference on Wednesday, July 8, 2015 at 8:30a.m. ET in New York, NY. Dr. Anido’s presentation will include an Aerie overview and ...

Advanced drug delivery applications: Overcoming bioavailability challenges, patient-centric drug design and innovative technologies

17 September 2015, Event, University of Tokyo, Sanjo Kaikan, Japan

New Breakthrough in Preventing Teen Drug Abuse

WHITE PLAINS, N.Y., July 1, 2015 /PRNewswire/ -- A recently published study sheds new light on how to prevent teen drug abuse. It also provides new evidence that the conventional wisdom regarding the timing of prevention efforts may be wrong. The current study shows that, with the right program, it's possible to cut high school drug abuse in half. The results of this study are especially imp...

Drug and device firm doctor payments reach $6.5bn for 2014

1,444 companies made payments to around 600,000 physicians and 1,100 hospitals

FDA cracks down on unapproved ear drops

The Food and Drug Administration says it plans to crack down on unapproved prescription ear drops often given to young children suffering from ear infections.

Merganser Biotech Inc. Appoints Remy Sukhija as Chief Operating Officer

Merganser Biotech Inc. (“Merganser”), a preclinical stage biotech company focused on the development of hepcidin mimetic peptides for the treatment of rare hematology and iron overload diseases, announced today that Remy Sukhija has been appointed to the role of Chief Operating Officer, effective immediately. “We are delighted to welcome Rem...

Baxalta Launches as a Global Biopharmaceutical Leader Dedicated to Patients with Orphan Diseases and Underserved Conditions

Baxalta to focus innovation on targeted therapies to advance leadership in hematology and immunology and to expand oncology business New products and indications planned to contribute $2.5 billion in sales by 2020, building on base of $6 billion in annual revenue Experienced management team driving a patient-focused stra...

Kamada Granted Key New Patent for Inhaled AAT and eFlow® Nebulizer System in Israel

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that the Israeli Patent Office (ILPO) has issued the patent titled, “SYSTEM FOR PULMONARY DELIVERY OF ALPHA-1 PROTEINASE INHIBITOR” under patent number, 193318. The patent is co-owned by Kamada and PARI PHARMA GMBH, the producers ...

Priority Review for MM-398 in Advanced Pancreatic Cancer

The FDA has granted a priority review for MM-398 as a second-line treatment for metastatic pancreatic cancer after the drug demonstrated improved survival.

AgBiome and Genective collaborate to create novel insect-resistant crops

RESEARCH TRIANGLE PARK, N.C. and PARIS, July 1, 2015 /PRNewswire/ -- Leading agricultural research firm AgBiome, and Genective, key developer of biotech crops, today announce a strategic partnership to accelerate the discovery of new generations of insect control traits. "Growers need new traits for insect control to counter the realities of advancing insect resistance. We are pleased to pa...

OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation

HONG KONG and FT LAUDERDALE, Florida, July 1, 2015 /PRNewswire/ -- OrbusNeich Medical, Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative medical devices for the treatment of vascular diseases, announced today that on May 13, 2015, it prevailed in a final opposition appeal hearing in the European Patent Office ("EPO") regarding European Patent EP 1 341 482 - STENT...

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

-- Experienced Healthcare Finance Leader Joins Leadership Team to Help Drive Continued Growth -- Editas Medicine, a leading genome editing company, today announced the appointment of Andrew Hack, M.D., Ph.D., as chief financial officer. Dr. Hack brings to Editas a deep understanding of capital markets, strong relationships across the financial communit...

Ideal Cures Pvt. Ltd.: Ideal Cures Becomes a Trendsetter - Receives EXCiPACT™ Certification for All Its Three Manufacturing Sites

IDEAL CURES PVT. LTD. is delighted to announce that it has received third EXCiPACT™ certificate for its manufacturing site located at Vasai. The plant at Vasai is the main manufacturing facility of the company and has received EXCiPACT™ certification for Film Coating Materials (INSTACOAT™, INSTANUTE™, INSTASPRAY™, and INSTAMASK™) and Extended C...

Novartis heart drug may see novel pricing plan

Swiss firm looking to risk share with payers based on clinical outcomes

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

U.S. FDA Approves Alternate Confirmation Test for Essure® Permanent Birth Control

WHIPPANY, N.J., July 1, 2015 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved the use of transvaginal ultrasound (TVU) as an alternate confirmation test for Essure® permanent birth control. A confirmation test must be given three months following the Essure® procedure to confirm that the device is properly placed and the ...

UK backs early access to BMS’s Opdivo for lung cancer

Patients with lung cancer in the UK can now get treatment with Bristol-Myers Squibb's Opdivo under a new scheme designed to accelerate access to new drugs.Opdivo (nivolumab) has been included in the UK's Early Access to Medicines Scheme (EAMS) for pa...

Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter

Executives at two Blue Cross and Blue Shield Plans and a Blues-owned pharmacy benefit manager share some of the strategies Blues plans are using to mitigate the financial impact of generic drug price inflation in the July issue of Atlantic Information Services’ The AIS Report on Blue Cross and Blue Shield Plans. The AIS Report is not affiliated with the Blue Cross and Blue Shield Association or ...

Diversified Service Options achieves Health Ethics Trust's Compliance Program certification

JACKSONVILLE, Fla., July 1, 2015 /PRNewswire/ -- Diversified Service Options, Inc., (Diversified) today announced that the company and its wholly-owned subsidiaries, First Coast Service Options and Novitas Solutions, have achieved the prestigious Health Ethics Trust's Compliance Program certification for their compliance program, Navigator. Diversified voluntarily submitted its program for the cer...



Advertisement
 
Advertisement
 

News Quicklinks